AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management
“The AtriClip franchise is one of the fastest growing parts of our
business and is a meaningful driver of our broadening presence in the
Afib market, which is vastly underserved and underpenetrated,” said
The LAA is a muscular pouch attached to the heart’s left atrium. In patients with Afib and other cardiac arrhythmias, blood can pool and form clots in the appendage, which may then leave the heart and cause strokes. One study concluded that more than 90 percent of detected blood clots in patients with atrial fibrillation are formed in the LAA.1
Patients who suffer from Afib have a 500 percent greater risk of stroke, compared with the general population.2 Afib-related strokes are associated with higher morbidity and mortality than non-Afib related strokes.3 Prior to the invention of the AtriClip system, cardiac surgeons typically addressed the LAA during open heart surgery by cutting it off or closing off the opening of LAA to the atrium. This approach required extra time on the heart-lung machine and posed a risk of hemorrhaging and or reopening over time.
“Since the launch of the AtriClip system in 2010, we have continued to add capabilities and new technology to the platform,” continued Carrel. “These innovations, most recently with the AtriClip PRO2™ device which was launched in 2016, have served to fuel continued adoption in both open and minimally-invasive cardiac surgery. Moving forward, we are excited about our robust pipeline of products coming to market.”
The AtriClip System is cleared by the
In February of 2016,
This randomized prospective study (AtriClip vs. no AtriClip) will evaluate resource utilization, including hospital length of stay, emergency room and/or hospital re-admissions, and costs associated with specific adverse events that may be related to atrial fibrillation through 365 days post index procedure.
About
_______________________________________
1
2 Benjamin EJ, Chen PS,
Bild DE, et al. Prevention of atrial fibrillation: report from a
national heart, lung, and blood institute workshop. Circulation.
2009
3 Marini C, De Santis F,
Sacco S, et al. “Contribution of atrial fibrillation to incidence and
outcome of ischemic stroke: results from a population-based
study.” Stroke. 2005 Jun; 36 (6):1115-9.
4 Data on
file at
View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005053/en/
Source:
AtriCure, Inc.
Media Relations
Valerie
Storch-Willhaus, 612-605-3311
Director, Corporate Marketing
and Communications
vstorch-willhaus@atricure.com
or
Investor
Relations
Andy Wade, 513-755-4564
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com